{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:21:39Z","timestamp":1789014099948,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early mortality (EM; death\u2009\u2264\u20096 months from diagnosis) has been reported in several newly diagnosed multiple myeloma (NDMM) trials. Before the era of novel agents, the incidence was 10%\u201014%. Causes of death included infections\/pneumonia, renal failure, refractory disease, and cardiac events. Staging systems, such as the revised International Staging System (r\u2010ISS), and prognostic factors including cytogenetics, lactate dehydrogenase levels, and myeloma\u2010specific factors, are useful to assess overall prognosis; however, they cannot predict EM. We evaluated patients treated with novel agents in the Connect MM<jats:sup>\u00ae<\/jats:sup> Registry and identified risk factors of the EM cohort. Eligible patients were enrolled in the registry within 60 days of diagnosis. Univariate and multivariate analyses were conducted to evaluate associations between baseline characteristics and EM. Prediction matrices for EM were constructed from a logistic model. Between September 2009 and December 2011, 1493 patients were enrolled in the registry and had adequate follow\u2010up. Of these patients, 102 (6.8%) had EM and 1391 (93.2%) survived for\u2009&gt;\u2009180 days. Baseline factors significantly associated with increased EM risk included age\u2009&gt;\u200975 years, higher Eastern Cooperative Oncology Group performance status, lower EQ\u20105D mobility score, higher ISS stage, lower platelet count, and prior hypertension. Renal insufficiency trended toward increased EM risk. These risk factors were incorporated into a prediction matrix for EM. The EM prediction matrix uses differential weighting of risk factors to calculate EM risk in patients with NDMM. Identifying patients at risk for EM may provide new opportunities to implement patient\u2010specific treatment strategies to improve outcomes.<\/jats:p>","DOI":"10.1002\/ajh.24796","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T16:59:11Z","timestamp":1495731551000},"page":"915-923","source":"Crossref","is-referenced-by-count":42,"title":["Recognition of early mortality in multiple myeloma by a prediction matrix"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-2353","authenticated-orcid":false,"given":"Howard","family":"Terebelo","sequence":"first","affiliation":[{"name":"Providence Cancer Center Southfield Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[{"name":"Maryland Oncology Hematology Columbia Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Indiana University Simon Cancer Center Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Division of Cellular Therapy Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[{"name":"Steeplechase Cancer Center Somerville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[{"name":"University of South Carolina Columbia South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Larkins","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"US Oncology Research, Rocky Mountain Cancer Centers Denver Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin J.","family":"Shah","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100330"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3195.3195","article-title":"Very early death (< 2 months) in myeloma is associated with advanced age, poor performance status and reduced use of novel agents, while early death within 12 months is associated with high risk features of both the disease and the patient","volume":"122","author":"Kastritis E","year":"2013","journal-title":"Blood."},{"key":"e_1_2_6_4_1","first-page":"489","article-title":"Risk stratification in multiple myeloma, part 1: characterization of high\u2010risk disease","volume":"11","author":"Biran N","year":"2013","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_6_5_1","first-page":"100","article-title":"Early mortality in elderly newly diagnosed multiple myeloma patients treate with novel agents: a pooled analysis of two large randomized pahse III trials","author":"Larocca A","year":"2015","journal-title":"Haematologica."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2086"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3981.3981","article-title":"Factors predicting early mortality in patients with newly diagnosed multiple myeloma","volume":"118","author":"Rana V","year":"2011","journal-title":"Blood."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0329"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00114-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep155"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.042093"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.12.002"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357394"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.33"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2619"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181c30fb2"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_22_1","unstructured":"European Society for Medical Oncology (ESMO). Performance scales: Karnofsky & ECOG scores.http:\/\/oncologypro.esmo.org\/Guidelines-Practice\/Practice-Tools\/Performance-Scales. Accessed October 27 2015."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01524.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24129"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-163329"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt483"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2113.2113","article-title":"Hypercalcemia remains an adverse prognostic factor for newly diagnosed patients with symptomatic multiple myeloma in the era of novel anti\u2010myeloma therapies, independently of age, ISS stage and treatment type: an analysis of 2129 patients","volume":"124","author":"Zomas A","year":"2014","journal-title":"Blood."},{"key":"e_1_2_6_31_1","first-page":"172","article-title":"Risk of early death in multiple myeloma","volume":"10","author":"Kumar S.","year":"2012","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23932"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2205"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.3996"},{"key":"e_1_2_6_37_1","unstructured":"GliklichR DreyerN LeavyMand eds. Registries for Evaluating Patient Outcomes: A User's Guide. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences Inc. a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)\u2010EHC111. Rockville MD: Agency for Healthcare Research and Quality. April2014.http:\/\/www.effectivehealthcare.ahrq.gov\/registries-guide-3.cfm."},{"key":"e_1_2_6_38_1","first-page":"S28","article-title":"Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities","volume":"31","author":"Yoshida K","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:07:37Z","timestamp":1695575257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1002\/ajh.24796"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24796","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}